MiMedx Group (NASDAQ:MDXG – Get Free Report) and Silence Therapeutics (NASDAQ:SLN – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations.
Valuation and Earnings
This table compares MiMedx Group and Silence Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MiMedx Group | $418.63 million | 1.62 | $48.58 million | $0.04 | 116.50 |
| Silence Therapeutics | $560,000.00 | 1,175.17 | -$88.61 million | ($1.28) | -8.54 |
Volatility & Risk
MiMedx Group has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500. Comparatively, Silence Therapeutics has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500.
Profitability
This table compares MiMedx Group and Silence Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MiMedx Group | 1.76% | 12.09% | 9.22% |
| Silence Therapeutics | -8,943.86% | -106.94% | -47.99% |
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for MiMedx Group and Silence Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MiMedx Group | 1 | 0 | 6 | 0 | 2.71 |
| Silence Therapeutics | 1 | 0 | 4 | 1 | 2.83 |
MiMedx Group currently has a consensus target price of $8.57, indicating a potential upside of 83.94%. Silence Therapeutics has a consensus target price of $53.50, indicating a potential upside of 389.48%. Given Silence Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Silence Therapeutics is more favorable than MiMedx Group.
Institutional & Insider Ownership
79.2% of MiMedx Group shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 2.5% of MiMedx Group shares are held by insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
MiMedx Group beats Silence Therapeutics on 8 of the 15 factors compared between the two stocks.
About MiMedx Group
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins. The company’s patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company’s products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.
About Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.
